Pegaptanib Sodium for Macular Edema Secondary to Central Retinal Vein Occlusion

Wroblewski, John J.; Wells, John A.; Gonzales, Christine R.

doi:10.1001/archophthalmol.2009.14

Cited by 85 publications

(64 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients with visual loss due to macular edema secondary to CRVO were randomly assigned to sham injection, 0.3 mg or 1 mg of pegaptanib sodium. A phase II trial indicated that 0.3 mg intravitreal pegaptanib given every 6 weeks over a 6-month follow-up improved VA by approximately 7 letters at 6 months [93]. The best treatment regimen and response to treatment in the long run still remain unclear.…”

Section: Managementmentioning

confidence: 99%

Management of Retinal Vein Occlusion – Consensus Document

et al. 2011

View full text Add to dashboard Cite

Retinal vein occlusion (RVO) can have severe consequences for the people affected by the disease, including visual loss with costly social repercussions. Currently, there is no European consensus with regard to the management of RVO. Following a careful review of the medical literature as well as the data from several clinical trials, a collaborative group of retina specialists put forth practical recommendations based on the best available scientific evidence for the clinical approach to RVO. Taking into consideration the recent advances in diagnostic tools and management options, the present document aims to provide the European ophthalmologists with guidelines for clinical practice to the benefit of their patients.

show abstract

Section: Managementmentioning

confidence: 99%

Management of Retinal Vein Occlusion – Consensus Document

et al. 2011

View full text Add to dashboard Cite

show abstract

“…In a multicenter randomized clinical trial, after the pegaptanib treatment, mean BCVA improved in CRVO with CME. However, the proportion of patients with vision improvement was not statistically significant [20]. In the CRUISE study, more than 40% of eyes gained 3 lines or more in the ranibizumab arms, in comparison to the 16% in the observation arm [5].…”

Section: Discussionmentioning

confidence: 82%

Intravitreal bevacizumab for treatment of serous macular detachment in central retinal vein occlusion

Çinal

Ziemssen

Bartz‐Schmidt

et al. 2010

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

show abstract

“…Results at week 30 showed that 36% of subjects treated with 0.3 mg of pegaptanib sodium and 39% treated with 1 mg gained ≥15 letters from baseline versus 28% sham-treated subjects [39]. The main problem with these drugs arises from the question of what will happen when injections are stopped.…”

Section: Central Retinal Vein Occlusionmentioning

confidence: 99%

Retinal Venous Occlusions: Diagnosis and Choice of Treatments

et al. 2013

View full text Add to dashboard Cite

Retinal vascular occlusive disorders constitute one of the major causes of blindness and impaired vision. There is marked controversy on their pathogeneses, clinical features and particularly their management. Recently, advances in clinical research added antivascular endothelial growth factor, corticosteroids and sustained-release implants to our armamentarium in the management of retinal vein occlusions. The purpose of our paper is to provide an update and a brief review on the current treatment options of retinal vein occlusions.

show abstract

Pegaptanib Sodium for Macular Edema Secondary to Central Retinal Vein Occlusion

Cited by 85 publications

References 73 publications

Management of Retinal Vein Occlusion – Consensus Document

Management of Retinal Vein Occlusion – Consensus Document

Intravitreal bevacizumab for treatment of serous macular detachment in central retinal vein occlusion

Retinal Venous Occlusions: Diagnosis and Choice of Treatments

Contact Info

Product

Resources

About